Identification

Name
Hydroflumethiazide
Accession Number
DB00774  (APRD01020)
Type
Small Molecule
Groups
Approved
Description

A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822)

Structure
Thumb
Synonyms
  • Dihydroflumethazide
  • Hidroflumetiazid
  • Hidroflumetiazida
  • Hydrofluméthiazide
  • Hydroflumethiazide
  • Hydroflumethiazidum
  • Idroflumetiazide
  • Metforylthiadiazin
International/Other Brands
Leodrine (Leo) / Saluron (Shire)
Categories
UNII
501CFL162R
CAS number
135-09-1
Weight
Average: 331.292
Monoisotopic: 330.990831754
Chemical Formula
C8H8F3N3O4S2
InChI Key
DMDGGSIALPNSEE-UHFFFAOYSA-N
InChI
InChI=1S/C8H8F3N3O4S2/c9-8(10,11)4-1-5-7(2-6(4)19(12,15)16)20(17,18)14-3-13-5/h1-2,13-14H,3H2,(H2,12,15,16)
IUPAC Name
1,1-dioxo-6-(trifluoromethyl)-3,4-dihydro-2H-1λ⁶,2,4-benzothiadiazine-7-sulfonamide
SMILES
NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1C(F)(F)F

Pharmacology

Indication

Used as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Also used in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension.

Structured Indications
Not Available
Pharmacodynamics

Hydroflumethiazide is an oral thiazide used to treat hypertension and edema. High blood pressure adds to the workload of the heart and arteries. If it continues for a long time, the heart and arteries may not function properly. This can damage the blood vessels of the brain, heart, and kidneys, resulting in a stroke, heart failure, or kidney failure. High blood pressure may also increase the risk of heart attacks. Like other thiazides, Hydroflumethiazide promotes water loss from the body (diuretics). Thiazides inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue.

Mechanism of action

Hydroflumethiazide is a thiazide diuretic that inhibits water reabsorption in the nephron by inhibiting the sodium-chloride symporter (SLC12A3) in the distal convoluted tubule, which is responsible for 5% of total sodium reabsorption. Normally, the sodium-chloride symporter transports sodium and chloride from the lumen into the epithelial cell lining the distal convoluted tubule. The energy for this is provided by a sodium gradient established by sodium-potassium ATPases on the basolateral membrane. Once sodium has entered the cell, it is transported out into the basolateral interstitium via the sodium-potassium ATPase, causing an increase in the osmolarity of the interstitium, thereby establishing an osmotic gradient for water reabsorption. By blocking the sodium-chloride symporter, Hydroflumethiazide effectively reduces the osmotic gradient and water reabsorption throughout the nephron.

TargetActionsOrganism
ASolute carrier family 12 member 1
inhibitor
Human
UCarbonic anhydrase 1
inhibitor
Human
UCarbonic anhydrase 2
inhibitor
Human
UCarbonic anhydrase 4
inhibitor
Human
UCarbonic anhydrase 9
inhibitor
Human
UCarbonic anhydrase 12
inhibitor
Human
USodium/potassium-transporting ATPase subunit alpha-1
other/unknown
Human
UCalcium-activated potassium channel subunit alpha-1
other/unknown
Human
Absorption

Hydroflumethiazide is incompletely but fairly rapidly absorbed from the gastrointestinal tract

Volume of distribution
Not Available
Protein binding

74%

Metabolism

Essentially unchanged

Route of elimination
Not Available
Half life

It appears to have a biphasic biological half-life with an estimated alpha-phase of about 2 hours and an estimated beta-phase of about 17 hours

Clearance
Not Available
Toxicity

Overdoses lead to diuresis, lethargy progressing to coma, with minimal cardiorespiratory depression and with or without significant serum electrolyte changes or dehydration.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Hydroflumethiazide Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-Bromoepiandrosterone16-Bromoepiandrosterone may increase the hypokalemic activities of Hydroflumethiazide.Investigational
19-norandrostenedione19-norandrostenedione may increase the hypokalemic activities of Hydroflumethiazide.Experimental, Illicit
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Hydroflumethiazide.Investigational
5-androstenedione5-androstenedione may increase the hypokalemic activities of Hydroflumethiazide.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Hydroflumethiazide.Experimental
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Hydroflumethiazide.Approved, Investigational
AcebutololHydroflumethiazide may increase the hypotensive activities of Acebutolol.Approved
AceclofenacThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Aceclofenac.Approved
AcemetacinThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Acemetacin.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Hydroflumethiazide.Withdrawn
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Acetyldigitoxin.Approved
AcetyldigoxinThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Acetyldigoxin.Experimental
Acetylsalicylic acidThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AclidiniumThe serum concentration of Hydroflumethiazide can be increased when it is combined with Aclidinium.Approved
AdapaleneThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Adapalene.Approved
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Hydroflumethiazide.Experimental
AlaproclateAlaproclate may increase the hyponatremic activities of Hydroflumethiazide.Experimental
AlclofenacThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Alclofenac.Approved, Withdrawn
AlclometasoneAlclometasone may increase the hypokalemic activities of Hydroflumethiazide.Approved
AlcuroniumThe serum concentration of Hydroflumethiazide can be increased when it is combined with Alcuronium.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Aldesleukin.Approved
AldosteroneAldosterone may increase the hypokalemic activities of Hydroflumethiazide.Experimental
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Hydroflumethiazide.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
AliskirenHydroflumethiazide may increase the hypotensive activities of Aliskiren.Approved, Investigational
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Hydroflumethiazide.Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Hydroflumethiazide.Approved
AlminoprofenThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Alminoprofen.Experimental
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Hydroflumethiazide.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Hydroflumethiazide.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Hydroflumethiazide.Illicit
AlprenololHydroflumethiazide may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanHydroflumethiazide may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmcinonideAmcinonide may increase the hypokalemic activities of Hydroflumethiazide.Approved
AmifostineHydroflumethiazide may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Amiloride.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Hydroflumethiazide.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Hydroflumethiazide.Approved
AmobarbitalAmobarbital may increase the orthostatic hypotensive activities of Hydroflumethiazide.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Hydroflumethiazide.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Amyl Nitrite.Approved
AndrographolideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Andrographolide.Investigational
AndrostenedioneAndrostenedione may increase the hypokalemic activities of Hydroflumethiazide.Experimental, Illicit
AnecortaveAnecortave may increase the hypokalemic activities of Hydroflumethiazide.Investigational
anecortave acetateanecortave acetate may increase the hypokalemic activities of Hydroflumethiazide.Investigational
AnisodamineThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Anisodamine.Investigational
Anisotropine MethylbromideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Anisotropine Methylbromide.Approved
AntipyrineThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Antipyrine.Approved
ApocyninThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Apocynin.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Hydroflumethiazide.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Apraclonidine.Approved
ApremilastThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Apremilast.Approved, Investigational
ArbutamineArbutamine may increase the hypokalemic activities of Hydroflumethiazide.Approved
ArformoterolArformoterol may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Hydroflumethiazide.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Hydroflumethiazide.Approved, Investigational
AtamestaneAtamestane may increase the hypokalemic activities of Hydroflumethiazide.Investigational
AtenololAtenolol may increase the hypotensive activities of Hydroflumethiazide.Approved
AtracuriumThe serum concentration of Hydroflumethiazide can be increased when it is combined with Atracurium.Experimental
Atracurium besylateThe serum concentration of Hydroflumethiazide can be increased when it is combined with Atracurium besylate.Approved
AtropineThe serum concentration of Hydroflumethiazide can be increased when it is combined with Atropine.Approved, Vet Approved
AzapropazoneThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Azapropazone.Withdrawn
AzelastineThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Azilsartan medoxomil.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Hydroflumethiazide.Investigational
BalsalazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Balsalazide.Approved, Investigational
BambuterolBambuterol may increase the hypokalemic activities of Hydroflumethiazide.Approved
BarbexacloneBarbexaclone may increase the orthostatic hypotensive activities of Hydroflumethiazide.Experimental
BarbitalBarbital may increase the orthostatic hypotensive activities of Hydroflumethiazide.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Hydroflumethiazide.Approved
Beclomethasone dipropionateBeclomethasone dipropionate may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Hydroflumethiazide.Investigational
BenactyzineThe serum concentration of Hydroflumethiazide can be increased when it is combined with Benactyzine.Withdrawn
BenazeprilBenazepril may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
BendazacThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Bendazac.Experimental
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Hydroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Hydroflumethiazide.Withdrawn
BenorilateThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Benorilate.Experimental
BenoxaprofenThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Benoxaprofen.Withdrawn
BenzatropineThe serum concentration of Hydroflumethiazide can be increased when it is combined with Benzatropine.Approved
BepridilHydroflumethiazide may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetamethasoneBetamethasone may increase the hypokalemic activities of Hydroflumethiazide.Approved, Vet Approved
BetaxololBetaxolol may increase the hypotensive activities of Hydroflumethiazide.Approved
BethanidineBethanidine may increase the hypotensive activities of Hydroflumethiazide.Approved
BevoniumThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Bevonium.Experimental
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Hydroflumethiazide.Experimental, Illicit, Withdrawn
BietaserpineBietaserpine may increase the hypotensive activities of Hydroflumethiazide.Experimental
BimatoprostHydroflumethiazide may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BiperidenThe serum concentration of Hydroflumethiazide can be increased when it is combined with Biperiden.Approved
BisoprololBisoprolol may increase the hypotensive activities of Hydroflumethiazide.Approved
BornaprineThe serum concentration of Hydroflumethiazide can be increased when it is combined with Bornaprine.Experimental
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Hydroflumethiazide.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
BQ-123Hydroflumethiazide may increase the hypotensive activities of BQ-123.Investigational
BretyliumHydroflumethiazide may increase the hypotensive activities of Bretylium.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Hydroflumethiazide.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Hydroflumethiazide.Experimental
BromfenacThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Bromfenac.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Hydroflumethiazide.Approved, Investigational
BucillamineThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Bucillamine.Investigational
BudesonideBudesonide may increase the hypokalemic activities of Hydroflumethiazide.Approved
BufexamacThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Bufexamac.Experimental
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Hydroflumethiazide.Withdrawn
BumadizoneThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Bumadizone.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Hydroflumethiazide.Approved, Investigational
BupranololHydroflumethiazide may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Hydroflumethiazide.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Hydroflumethiazide.Approved, Illicit, Vet Approved
CadralazineCadralazine may increase the hypotensive activities of Hydroflumethiazide.Experimental
CafedrineHydroflumethiazide may increase the hypotensive activities of Cafedrine.Investigational
CalcidiolHydroflumethiazide may increase the hypercalcemic activities of Calcidiol.Approved, Nutraceutical
CalcipotriolHydroflumethiazide may increase the hypercalcemic activities of Calcipotriol.Approved
CalciumHydroflumethiazide may decrease the excretion rate of Calcium which could result in a higher serum level.Nutraceutical
Calcium AcetateHydroflumethiazide may decrease the excretion rate of Calcium Acetate which could result in a higher serum level.Approved
Calcium CarbonateHydroflumethiazide may decrease the excretion rate of Calcium Carbonate which could result in a higher serum level.Approved
Calcium CitrateHydroflumethiazide may decrease the excretion rate of Calcium Citrate which could result in a higher serum level.Approved
Calcium glubionateHydroflumethiazide may decrease the excretion rate of Calcium glubionate which could result in a higher serum level.Approved
Calcium GluceptateHydroflumethiazide may decrease the excretion rate of Calcium Gluceptate which could result in a higher serum level.Approved
Calcium gluconateHydroflumethiazide may decrease the excretion rate of Calcium gluconate which could result in a higher serum level.Approved, Vet Approved
Calcium lactateHydroflumethiazide may decrease the excretion rate of Calcium lactate which could result in a higher serum level.Approved, Experimental, Vet Approved
Calcium lactate gluconateHydroflumethiazide may decrease the excretion rate of Calcium lactate gluconate which could result in a higher serum level.Experimental
Calcium laevulateHydroflumethiazide may decrease the excretion rate of Calcium laevulate which could result in a higher serum level.Experimental
Calcium pangamateHydroflumethiazide may decrease the excretion rate of Calcium pangamate which could result in a higher serum level.Experimental
Calcium PhosphateHydroflumethiazide may decrease the excretion rate of Calcium Phosphate which could result in a higher serum level.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Canagliflozin.Approved
CandesartanHydroflumethiazide may increase the hypotensive activities of Candesartan.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Hydroflumethiazide.Experimental
CaptoprilHydroflumethiazide may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Carbaspirin calcium.Experimental
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Hydroflumethiazide.Approved
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Hydroflumethiazide.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Hydroflumethiazide.Illicit, Vet Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Hydroflumethiazide.Withdrawn
CarprofenThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Carprofen.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the hypotensive activities of Hydroflumethiazide.Approved
CarvedilolHydroflumethiazide may increase the hypotensive activities of Carvedilol.Approved, Investigational
CaseinHydroflumethiazide may decrease the excretion rate of Casein which could result in a higher serum level.Approved
CastanospermineThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Castanospermine.Experimental
CelecoxibThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational
ChloroquineThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Chloroquine.Approved, Vet Approved
ChlorothiazideHydroflumethiazide may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphenoxamineThe serum concentration of Hydroflumethiazide can be increased when it is combined with Chlorphenoxamine.Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Hydroflumethiazide.Approved, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Hydroflumethiazide.Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Hydroflumethiazide.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Hydroflumethiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Choline magnesium trisalicylate.Approved
CiclesonideCiclesonide may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational
CicletanineHydroflumethiazide may increase the hypotensive activities of Cicletanine.Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Hydroflumethiazide.Experimental
CilazaprilHydroflumethiazide may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Hydroflumethiazide.Approved
CitalopramCitalopram may increase the hyponatremic activities of Hydroflumethiazide.Approved
ClenbuterolClenbuterol may increase the hypokalemic activities of Hydroflumethiazide.Approved, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Clevidipine.Approved
ClobetasolClobetasol may increase the hypokalemic activities of Hydroflumethiazide.Investigational
Clobetasol propionateClobetasol propionate may increase the hypokalemic activities of Hydroflumethiazide.Approved
ClobetasoneClobetasone may increase the hypokalemic activities of Hydroflumethiazide.Approved
ClocortoloneClocortolone may increase the hypokalemic activities of Hydroflumethiazide.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Hydroflumethiazide.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Hydroflumethiazide.Approved, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Hydroflumethiazide.Approved
ClonixinThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Clonixin.Approved
CloranololHydroflumethiazide may increase the hypotensive activities of Cloranolol.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Hydroflumethiazide.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Hydroflumethiazide.Approved, Illicit
ColesevelamColesevelam can cause a decrease in the absorption of Hydroflumethiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Hydroflumethiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Hydroflumethiazide.Approved, Investigational
Cortexolone 17α-propionateCortexolone 17α-propionate may increase the hypokalemic activities of Hydroflumethiazide.Investigational
CorticosteroneCorticosterone may increase the hypokalemic activities of Hydroflumethiazide.Experimental
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Hydroflumethiazide.Approved
CryptenamineHydroflumethiazide may increase the hypotensive activities of Cryptenamine.Approved
CurcuminThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Curcumin.Investigational
CyclopenthiazideHydroflumethiazide may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclopentolateThe serum concentration of Hydroflumethiazide can be increased when it is combined with Cyclopentolate.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Cyclophosphamide.Approved, Investigational
CyclothiazideCyclothiazide may increase the hypotensive activities of Hydroflumethiazide.Approved
CymarinThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Cymarin.Experimental
D-LimoneneThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with D-Limonene.Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the hyponatremic activities of Hydroflumethiazide.Investigational
DarifenacinThe serum concentration of Hydroflumethiazide can be increased when it is combined with Darifenacin.Approved, Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Hydroflumethiazide.Approved
DelaprilHydroflumethiazide may increase the hypotensive activities of Delapril.Experimental
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Hydroflumethiazide.Investigational
DeserpidineHydroflumethiazide may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Hydroflumethiazide.Approved
DeslanosideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Deslanoside.Approved
DesloratadineThe serum concentration of Hydroflumethiazide can be increased when it is combined with Desloratadine.Approved, Investigational
DesoximetasoneDesoximetasone may increase the hypokalemic activities of Hydroflumethiazide.Approved
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hypokalemic activities of Hydroflumethiazide.Approved
Desoxycorticosterone PivalateDesoxycorticosterone Pivalate may increase the hypokalemic activities of Hydroflumethiazide.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the hyponatremic activities of Hydroflumethiazide.Approved
DexamethasoneDexamethasone may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hypokalemic activities of Hydroflumethiazide.Vet Approved
DexetimideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Dexetimide.Withdrawn
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Hydroflumethiazide.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Hydroflumethiazide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Hydroflumethiazide.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Hydroflumethiazide.Approved
DiazoxideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Diazoxide.Approved
DiclofenacThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Diclofenamide.Approved
DicyclomineThe serum concentration of Hydroflumethiazide can be increased when it is combined with Dicyclomine.Approved
diethylnorspermineHydroflumethiazide may increase the hypotensive activities of diethylnorspermine.Investigational
DifenpiramideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Difenpiramide.Experimental
DiflorasoneDiflorasone may increase the hypokalemic activities of Hydroflumethiazide.Approved
DiflunisalThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Diflunisal.Approved
DifluocortoloneDifluocortolone may increase the hypokalemic activities of Hydroflumethiazide.Approved
DifluprednateDifluprednate may increase the hypokalemic activities of Hydroflumethiazide.Approved
DigitoxinThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Digitoxin.Approved
DigoxinThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Digoxin.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Hydroflumethiazide.Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Hydroflumethiazide.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Hydroflumethiazide.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Hydroflumethiazide.Experimental, Illicit
DihydrotachysterolHydroflumethiazide may increase the hypercalcemic activities of Dihydrotachysterol.Approved
DiltiazemDiltiazem may increase the hypotensive activities of Hydroflumethiazide.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Dinutuximab.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Hydroflumethiazide.Approved, Illicit
DipivefrinDipivefrin may increase the hypokalemic activities of Hydroflumethiazide.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Dipyridamole.Approved
DobutamineDobutamine may increase the hypokalemic activities of Hydroflumethiazide.Approved
DofetilideHydroflumethiazide may increase the QTc-prolonging activities of Dofetilide.Approved
DorzolamideHydroflumethiazide may increase the hypotensive activities of Dorzolamide.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Hydroflumethiazide.Approved
DoxercalciferolHydroflumethiazide may increase the hypercalcemic activities of Doxercalciferol.Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Hydroflumethiazide.Investigational
DroxicamThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Droxicam.Approved
DroxidopaDroxidopa may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Hydroflumethiazide.Approved
DuloxetineHydroflumethiazide may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Duvelisib.Investigational
E-6201The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with E-6201.Investigational
EfonidipineHydroflumethiazide may increase the hypotensive activities of Efonidipine.Approved
EmeproniumThe serum concentration of Hydroflumethiazide can be increased when it is combined with Emepronium.Experimental
EmpagliflozinThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Empagliflozin.Approved
EnalaprilEnalapril may increase the hypotensive activities of Hydroflumethiazide.Approved, Vet Approved
EnalaprilatHydroflumethiazide may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Hydroflumethiazide.Experimental
EpanololHydroflumethiazide may increase the hypotensive activities of Epanolol.Experimental
EphedraEphedra may increase the hypokalemic activities of Hydroflumethiazide.Approved, Nutraceutical, Withdrawn
EpinephrineEpinephrine may increase the hypokalemic activities of Hydroflumethiazide.Approved, Vet Approved
EpirizoleThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Epirizole.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Eplerenone.Approved
EpoprostenolHydroflumethiazide may increase the hypotensive activities of Epoprostenol.Approved
EprosartanHydroflumethiazide may increase the hypotensive activities of Eprosartan.Approved
EquileninEquilenin may increase the hypokalemic activities of Hydroflumethiazide.Experimental
EquilinEquilin may increase the hypokalemic activities of Hydroflumethiazide.Approved
ErgocalciferolHydroflumethiazide may increase the hypercalcemic activities of Ergocalciferol.Approved, Nutraceutical
EscitalopramEscitalopram may increase the hyponatremic activities of Hydroflumethiazide.Approved, Investigational
EsmololThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Esmolol.Approved
EstroneEstrone may increase the hypokalemic activities of Hydroflumethiazide.Approved
Estrone sulfateEstrone sulfate may increase the hypokalemic activities of Hydroflumethiazide.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Etacrynic acid.Approved
EtanautineThe serum concentration of Hydroflumethiazide can be increased when it is combined with Etanautine.Experimental
EtanerceptThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Etanercept.Approved, Investigational
EthanolEthanol may increase the orthostatic hypotensive activities of Hydroflumethiazide.Approved
EthenzamideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Ethenzamide.Experimental
EthopropazineThe serum concentration of Hydroflumethiazide can be increased when it is combined with Ethopropazine.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Hydroflumethiazide.Approved, Illicit
EtodolacThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Etofenamate.Approved
EtoperidoneEtoperidone may increase the hyponatremic activities of Hydroflumethiazide.Approved
EtoricoxibThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Etoricoxib.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Hydroflumethiazide.Illicit, Vet Approved
EtybenzatropineThe serum concentration of Hydroflumethiazide can be increased when it is combined with Etybenzatropine.Experimental
Evening primrose oilThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Evening primrose oil.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Hydroflumethiazide.Approved, Investigational
exisulindThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with exisulind.Investigational
FelbinacThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Felbinac.Experimental
FelodipineHydroflumethiazide may increase the hypotensive activities of Felodipine.Approved, Investigational
FenbufenThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Fenbufen.Approved
FenoldopamHydroflumethiazide may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Fenoprofen.Approved
FenoterolFenoterol may increase the hypokalemic activities of Hydroflumethiazide.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Hydroflumethiazide.Approved, Illicit, Investigational, Vet Approved
FentiazacThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Fentiazac.Experimental
FeprazoneThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Feprazone.Experimental
Ferulic acidThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Ferulic acid.Experimental
FesoterodineThe serum concentration of Hydroflumethiazide can be increased when it is combined with Fesoterodine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Hydroflumethiazide.Approved
FloctafenineThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Floctafenine.Approved, Withdrawn
fluasteronefluasterone may increase the hypokalemic activities of Hydroflumethiazide.Investigational
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Hydroflumethiazide.Approved
FlumethasoneFlumethasone may increase the hypokalemic activities of Hydroflumethiazide.Approved, Vet Approved
FlunixinThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Flunixin.Vet Approved
FlunoxaprofenThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Flunoxaprofen.Experimental
Fluocinolone AcetonideFluocinolone Acetonide may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational, Vet Approved
FluocinonideFluocinonide may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational
FluocortoloneFluocortolone may increase the hypokalemic activities of Hydroflumethiazide.Approved, Withdrawn
FluorometholoneFluorometholone may increase the hypokalemic activities of Hydroflumethiazide.Approved
FluoxetineFluoxetine may increase the hyponatremic activities of Hydroflumethiazide.Approved, Vet Approved
FluprednideneFluprednidene may increase the hypokalemic activities of Hydroflumethiazide.Approved, Withdrawn
FluprednisoloneFluprednisolone may increase the hypokalemic activities of Hydroflumethiazide.Approved
FlurandrenolideFlurandrenolide may increase the hypokalemic activities of Hydroflumethiazide.Approved
FlurbiprofenThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Flurbiprofen.Approved, Investigational
FluvoxamineFluvoxamine may increase the hyponatremic activities of Hydroflumethiazide.Approved, Investigational
FormestaneFormestane may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational, Withdrawn
FormoterolFormoterol may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational
FosinoprilFosinopril may increase the hypotensive activities of Hydroflumethiazide.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Hydroflumethiazide.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Furosemide.Approved, Vet Approved
GallamineThe serum concentration of Hydroflumethiazide can be increased when it is combined with Gallamine.Experimental
Gallamine TriethiodideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Gallamine Triethiodide.Approved
GitoformateThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Gitoformate.Experimental
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Hydroflumethiazide.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Hydroflumethiazide.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Hydroflumethiazide.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Hydroflumethiazide.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Hydroflumethiazide.Approved
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Hydroflumethiazide.Approved
GlycopyrroniumThe serum concentration of Hydroflumethiazide can be increased when it is combined with Glycopyrronium.Approved, Investigational, Vet Approved
GuacetisalThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Guacetisal.Experimental
GuanabenzGuanabenz may increase the hypotensive activities of Hydroflumethiazide.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Hydroflumethiazide.Approved
GuanazodineHydroflumethiazide may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Hydroflumethiazide.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
GuanoclorHydroflumethiazide may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzHydroflumethiazide may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanHydroflumethiazide may increase the hypotensive activities of Guanoxan.Experimental
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Hydroflumethiazide.Investigational
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Hydroflumethiazide.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Hydroflumethiazide.Experimental
HE3286HE3286 may increase the hypokalemic activities of Hydroflumethiazide.Investigational
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Hydroflumethiazide.Approved, Illicit
HexamethoniumThe serum concentration of Hydroflumethiazide can be increased when it is combined with Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the orthostatic hypotensive activities of Hydroflumethiazide.Approved
HigenamineThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Higenamine.Investigational
HomatropineThe serum concentration of Hydroflumethiazide can be increased when it is combined with Homatropine.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Hydroflumethiazide.Experimental
HydralazineHydralazine may increase the hypotensive activities of Hydroflumethiazide.Approved
HydrochlorothiazideHydroflumethiazide may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Hydroflumethiazide.Approved, Illicit
HydrocortisoneHydrocortisone may increase the hypokalemic activities of Hydroflumethiazide.Approved, Vet Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Hydroflumethiazide.Approved, Illicit
HyoscyamineThe serum concentration of Hydroflumethiazide can be increased when it is combined with Hyoscyamine.Approved
IbuprofenThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Ibuprofen.Approved
IbuproxamThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Ibuproxam.Withdrawn
IcatibantThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Icatibant.Approved
IloprostIloprost may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Imidapril.Investigational
Imidazole salicylateThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Imidazole salicylate.Experimental
ImipramineThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Imipramine.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of Hydroflumethiazide.Approved
IndalpineIndalpine may increase the hyponatremic activities of Hydroflumethiazide.Investigational, Withdrawn
IndapamideHydroflumethiazide may increase the hypotensive activities of Indapamide.Approved
IndenololHydroflumethiazide may increase the hypotensive activities of Indenolol.Withdrawn
IndobufenThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Indobufen.Investigational
IndomethacinThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Indomethacin.Approved, Investigational
IndoprofenThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Indoprofen.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Hydroflumethiazide.Withdrawn
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Hydroflumethiazide.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Hydroflumethiazide.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Hydroflumethiazide.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Hydroflumethiazide.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Hydroflumethiazide.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Hydroflumethiazide.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Hydroflumethiazide.Approved
Ipratropium bromideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Ipratropium bromide.Approved
IproclozideIproclozide may increase the hypotensive activities of Hydroflumethiazide.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Hydroflumethiazide.Withdrawn
IrbesartanHydroflumethiazide may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Hydroflumethiazide.Approved
IsoetarineIsoetarine may increase the hypokalemic activities of Hydroflumethiazide.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Isoflurane.Approved, Vet Approved
IsoprenalineIsoprenaline may increase the hypokalemic activities of Hydroflumethiazide.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Isosorbide Mononitrate.Approved
IsoxicamThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Isoxsuprine.Approved, Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Hydroflumethiazide.Approved
IstaroximeIstaroxime may increase the hypokalemic activities of Hydroflumethiazide.Investigational
IvabradineHydroflumethiazide may increase the arrhythmogenic activities of Ivabradine.Approved
KebuzoneThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Kebuzone.Experimental
KetanserinKetanserin may increase the hypotensive activities of Hydroflumethiazide.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Hydroflumethiazide.Approved
KetoprofenThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
KetorolacThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Ketorolac.Approved
LabetalolLabetalol may increase the hypotensive activities of Hydroflumethiazide.Approved
LacidipineHydroflumethiazide may increase the hypotensive activities of Lacidipine.Approved
Lanatoside CThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Lanatoside C.Experimental
LatanoprostLatanoprost may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
LeflunomideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Leflunomide.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Levobupivacaine.Approved
LevodopaHydroflumethiazide may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Hydroflumethiazide.Approved
LevomilnacipranLevomilnacipran may increase the hyponatremic activities of Hydroflumethiazide.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Hydroflumethiazide.Approved
LevosalbutamolLevosalbutamol may increase the hypokalemic activities of Hydroflumethiazide.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Levosimendan.Approved, Investigational
LicoriceLicorice may increase the hypokalemic activities of Hydroflumethiazide.Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Hydroflumethiazide.Approved
LinsidomineHydroflumethiazide may increase the hypotensive activities of Linsidomine.Experimental
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Hydroflumethiazide.Approved
LisinoprilLisinopril may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
LisofyllineThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Lisofylline.Investigational
LithiumHydroflumethiazide may decrease the excretion rate of Lithium which could result in a higher serum level.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Hydroflumethiazide.Illicit
LofexidineHydroflumethiazide may increase the hypotensive activities of Lofexidine.Approved, Investigational
LonazolacThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Lonazolac.Experimental
LornoxicamThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Lornoxicam.Approved
LosartanLosartan may increase the hypotensive activities of Hydroflumethiazide.Approved
LoxoprofenThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Loxoprofen.Approved
LumiracoxibThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Lumiracoxib.Approved, Investigational
MacitentanHydroflumethiazide may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Magnesium salicylate.Approved
ManidipineHydroflumethiazide may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Mannitol.Approved, Investigational
MasoprocolThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Masoprocol.Approved
MazaticolThe serum concentration of Hydroflumethiazide can be increased when it is combined with Mazaticol.Experimental
ME-609ME-609 may increase the hypokalemic activities of Hydroflumethiazide.Investigational
MebanazineMebanazine may increase the hypotensive activities of Hydroflumethiazide.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Mecamylamine.Approved
Meclofenamic acidThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
MedrysoneMedrysone may increase the hypokalemic activities of Hydroflumethiazide.Approved
Mefenamic acidThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Mefenamic acid.Approved
MelengestrolMelengestrol may increase the hypokalemic activities of Hydroflumethiazide.Vet Approved
MeloxicamThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Meloxicam.Approved, Vet Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Hydroflumethiazide.Experimental
MesalazineThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Mesalazine.Approved
MetamizoleThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Metamizole.Withdrawn
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Hydroflumethiazide.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Hydroflumethiazide.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Hydroflumethiazide.Approved, Illicit
MethanthelineThe serum concentration of Hydroflumethiazide can be increased when it is combined with Methantheline.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the orthostatic hypotensive activities of Hydroflumethiazide.Approved
MethoserpidineHydroflumethiazide may increase the hypotensive activities of Methoserpidine.Experimental
MethyclothiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Methyclothiazide.Approved
MethyldopaHydroflumethiazide may increase the hypotensive activities of Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Hydroflumethiazide.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Hydroflumethiazide.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the orthostatic hypotensive activities of Hydroflumethiazide.Approved
MethylprednisoloneMethylprednisolone may increase the hypokalemic activities of Hydroflumethiazide.Approved, Vet Approved
MetildigoxinThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Metildigoxin.Experimental
MetipranololHydroflumethiazide may increase the hypotensive activities of Metipranolol.Approved
MetixeneThe serum concentration of Hydroflumethiazide can be increased when it is combined with Metixene.Approved
MetolazoneMetolazone may increase the hypotensive activities of Hydroflumethiazide.Approved
MetoprololMetoprolol may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
MetyrosineHydroflumethiazide may increase the hypotensive activities of Metyrosine.Approved
MibefradilHydroflumethiazide may increase the hypotensive activities of Mibefradil.Withdrawn
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Hydroflumethiazide.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Hydroflumethiazide.Approved
MilnacipranMilnacipran may increase the hyponatremic activities of Hydroflumethiazide.Approved
MinaprineMinaprine may increase the hypotensive activities of Hydroflumethiazide.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Hydroflumethiazide.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Hydroflumethiazide.Investigational
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Hydroflumethiazide.Approved, Investigational
MizoribineThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Hydroflumethiazide.Approved
MoexiprilMoexipril may increase the hypotensive activities of Hydroflumethiazide.Approved
MofebutazoneThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Mofebutazone.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Hydroflumethiazide.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Hydroflumethiazide.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Hydroflumethiazide.Approved
MuzolimineHydroflumethiazide may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Mycophenolic acid.Approved
NabiloneThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Nabilone.Approved, Investigational
NabumetoneThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Nabumetone.Approved
NadololHydroflumethiazide may increase the hypotensive activities of Nadolol.Approved
NafamostatThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Nafamostat.Approved, Investigational
NaftifineThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Naftifine.Approved
NaftopidilHydroflumethiazide may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Hydroflumethiazide.Approved
NaproxenThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Naproxen.Approved, Vet Approved
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Hydroflumethiazide.Approved, Investigational
NCX 1022NCX 1022 may increase the hypokalemic activities of Hydroflumethiazide.Investigational
NebivololHydroflumethiazide may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneNefazodone may increase the hyponatremic activities of Hydroflumethiazide.Approved, Withdrawn
NepafenacThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Nepafenac.Approved
NesiritideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Hydroflumethiazide.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Hydroflumethiazide.Approved
NicomorphineThe risk or severity of adverse effects can be increased when Nicomorphine is combined with Hydroflumethiazide.Experimental
NicorandilNicorandil may increase the hypotensive activities of Hydroflumethiazide.Approved
NifedipineThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Nifedipine.Approved
NifenazoneThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Nifenazone.Experimental
Niflumic AcidThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Niflumic Acid.Approved
NiguldipineHydroflumethiazide may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineHydroflumethiazide may increase the hypotensive activities of Nilvadipine.Approved
NimesulideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Nimesulide.Approved, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Hydroflumethiazide.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Hydroflumethiazide.Approved
NitrendipineHydroflumethiazide may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Nitric Oxide.Approved
NitroaspirinThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Nitroglycerin.Approved, Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Hydroflumethiazide.Approved
NorepinephrineNorepinephrine may increase the hypokalemic activities of Hydroflumethiazide.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Hydroflumethiazide.Approved, Illicit
ObinutuzumabHydroflumethiazide may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Hydroflumethiazide.Withdrawn
OleandrinThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Oleandrin.Experimental
Oleoyl-estroneOleoyl-estrone may increase the hypokalemic activities of Hydroflumethiazide.Investigational
OlmesartanOlmesartan may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
OlodaterolOlodaterol may increase the hypokalemic activities of Hydroflumethiazide.Approved
OlopatadineThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Olopatadine.Approved
OlsalazineThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Olsalazine.Approved
OmapatrilatHydroflumethiazide may increase the hypotensive activities of Omapatrilat.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Hydroflumethiazide.Approved, Illicit
OrciprenalineOrciprenaline may increase the hypokalemic activities of Hydroflumethiazide.Approved
OrgoteinThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Orgotein.Vet Approved
OrphenadrineThe serum concentration of Hydroflumethiazide can be increased when it is combined with Orphenadrine.Approved
OtiloniumThe serum concentration of Hydroflumethiazide can be increased when it is combined with Otilonium.Experimental
OuabainThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Ouabain.Approved
OxaprozinThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Oxaprozin.Approved
OxcarbazepineThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Oxcarbazepine.Approved
OxitropiumThe serum concentration of Hydroflumethiazide can be increased when it is combined with Oxitropium.Investigational
OxprenololHydroflumethiazide may increase the hypotensive activities of Oxprenolol.Approved
OxybutyninThe serum concentration of Hydroflumethiazide can be increased when it is combined with Oxybutynin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Hydroflumethiazide.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Hydroflumethiazide.Approved, Investigational, Vet Approved
OxyphenbutazoneThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Oxyphenbutazone.Withdrawn
OxyphenoniumThe serum concentration of Hydroflumethiazide can be increased when it is combined with Oxyphenonium.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Paclitaxel.Approved, Vet Approved
PancuroniumThe serum concentration of Hydroflumethiazide can be increased when it is combined with Pancuronium.Approved
PapaverineThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Papaverine.Approved
ParamethasoneParamethasone may increase the hypokalemic activities of Hydroflumethiazide.Approved
ParecoxibThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Hydroflumethiazide.Approved
ParicalcitolHydroflumethiazide may increase the hypercalcemic activities of Paricalcitol.Approved, Investigational
ParoxetineParoxetine may increase the hyponatremic activities of Hydroflumethiazide.Approved, Investigational
ParthenolideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Parthenolide.Investigational
PenbutololHydroflumethiazide may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Hydroflumethiazide.Approved, Vet Approved
PentobarbitalPentobarbital may increase the orthostatic hypotensive activities of Hydroflumethiazide.Approved, Vet Approved
PentoliniumThe serum concentration of Hydroflumethiazide can be increased when it is combined with Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
PerindoprilHydroflumethiazide may increase the hypotensive activities of Perindopril.Approved
PeruvosideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Peruvoside.Experimental
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Hydroflumethiazide.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Hydroflumethiazide.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Hydroflumethiazide.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Hydroflumethiazide.Approved, Withdrawn
PhenglutarimideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Phenglutarimide.Experimental
PheniprazinePheniprazine may increase the hypotensive activities of Hydroflumethiazide.Withdrawn
PhenobarbitalPhenobarbital may increase the orthostatic hypotensive activities of Hydroflumethiazide.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Hydroflumethiazide.Experimental
PhenoxybenzamineHydroflumethiazide may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Hydroflumethiazide.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Hydroflumethiazide.Approved
PhenylbutazoneThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the hypokalemic activities of Hydroflumethiazide.Approved, Vet Approved, Withdrawn
PimecrolimusThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Pimecrolimus.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Hydroflumethiazide.Withdrawn
PindololHydroflumethiazide may increase the hypotensive activities of Pindolol.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Hydroflumethiazide.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Pipamperone.Approved
PipecuroniumThe serum concentration of Hydroflumethiazide can be increased when it is combined with Pipecuronium.Approved
PirbuterolPirbuterol may increase the hypokalemic activities of Hydroflumethiazide.Approved
PirenzepineThe serum concentration of Hydroflumethiazide can be increased when it is combined with Pirenzepine.Approved
PirfenidoneThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Pirfenidone.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Hydroflumethiazide.Investigational
PirlindolePirlindole may increase the hypotensive activities of Hydroflumethiazide.Approved
PiroxicamThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Piroxicam.Approved, Investigational
PirprofenThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Pirprofen.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Hydroflumethiazide.Withdrawn
PolythiazideHydroflumethiazide may increase the hypotensive activities of Polythiazide.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Pramipexole.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Hydroflumethiazide.Approved, Investigational
PranoprofenThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Pranoprofen.Experimental
PrasteronePrasterone may increase the hypokalemic activities of Hydroflumethiazide.Approved, Nutraceutical
Prasterone sulfatePrasterone sulfate may increase the hypokalemic activities of Hydroflumethiazide.Investigational
PrazosinPrazosin may increase the hypotensive activities of Hydroflumethiazide.Approved
PrednicarbatePrednicarbate may increase the hypokalemic activities of Hydroflumethiazide.Approved
PrednisolonePrednisolone may increase the hypokalemic activities of Hydroflumethiazide.Approved, Vet Approved
PrednisonePrednisone may increase the hypokalemic activities of Hydroflumethiazide.Approved, Vet Approved
PregnenolonePregnenolone may increase the hypokalemic activities of Hydroflumethiazide.Experimental
PrimidonePrimidone may increase the orthostatic hypotensive activities of Hydroflumethiazide.Approved, Vet Approved
ProcaterolProcaterol may increase the hypokalemic activities of Hydroflumethiazide.Approved
ProcyclidineThe serum concentration of Hydroflumethiazide can be increased when it is combined with Procyclidine.Approved
ProglumetacinThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Proglumetacin.Experimental
PropacetamolThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Propacetamol.Approved
PropanthelineThe serum concentration of Hydroflumethiazide can be increased when it is combined with Propantheline.Approved
PropiverineThe serum concentration of Hydroflumethiazide can be increased when it is combined with Propiverine.Investigational
PropofolThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Propofol.Approved, Investigational, Vet Approved
PropranololPropranolol may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
PropyphenazoneThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Propyphenazone.Experimental
ProquazoneThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Proquazone.Experimental
ProscillaridinThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Proscillaridin.Experimental
PTC299The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with PTC299.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Quetiapine.Approved
QuinaprilHydroflumethiazide may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinidineThe serum concentration of Hydroflumethiazide can be increased when it is combined with Quinidine.Approved
QuinineQuinine may increase the hypotensive activities of Hydroflumethiazide.Approved
RamiprilRamipril may increase the hypotensive activities of Hydroflumethiazide.Approved
RasagilineRasagiline may increase the hypotensive activities of Hydroflumethiazide.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Hydroflumethiazide.Approved
RemikirenRemikiren may increase the hypotensive activities of Hydroflumethiazide.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Hydroflumethiazide.Approved, Investigational
RescinnamineHydroflumethiazide may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Hydroflumethiazide.Approved
ResveratrolThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Resveratrol.Experimental, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Hydroflumethiazide.Investigational
RimexoloneRimexolone may increase the hypokalemic activities of Hydroflumethiazide.Approved
RiociguatHydroflumethiazide may increase the hypotensive activities of Riociguat.Approved
RisperidoneHydroflumethiazide may increase the hypotensive activities of Risperidone.Approved, Investigational
RitodrineRitodrine may increase the hypokalemic activities of Hydroflumethiazide.Approved
RituximabHydroflumethiazide may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Rofecoxib.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Ropivacaine.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Hydroflumethiazide.Approved, Investigational
RotigotineThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Hydroflumethiazide.Withdrawn
SalbutamolSalbutamol may increase the hypokalemic activities of Hydroflumethiazide.Approved, Vet Approved
SalicylamideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Salicylamide.Approved
Salicylic acidThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Salicylic acid.Approved, Vet Approved
SalmeterolSalmeterol may increase the hypokalemic activities of Hydroflumethiazide.Approved
SalsalateThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Salsalate.Approved
SaprisartanHydroflumethiazide may increase the hypotensive activities of Saprisartan.Experimental
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Hydroflumethiazide.Approved
ScopolamineThe serum concentration of Hydroflumethiazide can be increased when it is combined with Scopolamine.Approved
Scopolamine butylbromideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Scopolamine butylbromide.Approved, Vet Approved
SecobarbitalSecobarbital may increase the orthostatic hypotensive activities of Hydroflumethiazide.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational, Vet Approved
SelexipagHydroflumethiazide may increase the hypotensive activities of Selexipag.Approved
SemapimodThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Semapimod.Investigational
SeratrodastThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Seratrodast.Approved
SerrapeptaseThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Serrapeptase.Investigational
SertralineSertraline may increase the hyponatremic activities of Hydroflumethiazide.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Hydroflumethiazide.Approved, Investigational
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Hydroflumethiazide.Approved, Investigational
SitaxentanHydroflumethiazide may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Sodium Nitrite.Approved
Sodium phosphateHydroflumethiazide may increase the nephrotoxic activities of Sodium phosphate.Approved
SolifenacinThe serum concentration of Hydroflumethiazide can be increased when it is combined with Solifenacin.Approved
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Hydroflumethiazide.Investigational
SotalolThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Sotalol.Approved
SpiraprilHydroflumethiazide may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Spironolactone.Approved
SRT501The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with SRT501.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Hydroflumethiazide.Approved, Investigational
SulfasalazineThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Sulfasalazine.Approved
SulindacThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Sulindac.Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Hydroflumethiazide.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Sulpiride.Approved
SuprofenThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Suprofen.Approved, Withdrawn
SuxibuzoneThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Suxibuzone.Experimental
TadalafilTadalafil may increase the antihypertensive activities of Hydroflumethiazide.Approved, Investigational
TalinololHydroflumethiazide may increase the hypotensive activities of Talinolol.Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Tamsulosin.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Hydroflumethiazide.Approved
TarenflurbilThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Tarenflurbil.Investigational
TelmisartanHydroflumethiazide may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilHydroflumethiazide may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenidapThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Tenidap.Experimental
TenoxicamThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Tenoxicam.Approved
TepoxalinThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Terazosin.Approved
TerbutalineTerbutaline may increase the hypokalemic activities of Hydroflumethiazide.Approved
TeriflunomideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Teriflunomide.Approved
TerlipressinHydroflumethiazide may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrahydropalmatineHydroflumethiazide may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Thalidomide.Approved, Investigational, Withdrawn
TheodrenalineHydroflumethiazide may increase the hypotensive activities of Theodrenaline.Investigational
ThiamylalThiamylal may increase the orthostatic hypotensive activities of Hydroflumethiazide.Approved, Vet Approved
ThiopentalThiopental may increase the orthostatic hypotensive activities of Hydroflumethiazide.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Thioridazine.Withdrawn
Tiaprofenic acidThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Tiaprofenic acid.Approved
TiboloneHydroflumethiazide may increase the hypotensive activities of Tibolone.Approved
TicrynafenHydroflumethiazide may increase the hypotensive activities of Ticrynafen.Withdrawn
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Hydroflumethiazide.Experimental
TimololTimolol may increase the hypotensive activities of Hydroflumethiazide.Approved
TinoridineThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Tinoridine.Investigational
TiotropiumThe serum concentration of Hydroflumethiazide can be increased when it is combined with Tiotropium.Approved
TixocortolTixocortol may increase the hypokalemic activities of Hydroflumethiazide.Approved
TizanidineThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Tizanidine.Approved
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Hydroflumethiazide.Approved
TolazolineHydroflumethiazide may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Hydroflumethiazide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Tolfenamic Acid.Approved
TolmetinThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Tolmetin.Approved
TolonidineHydroflumethiazide may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Hydroflumethiazide.Approved
TolterodineThe serum concentration of Hydroflumethiazide can be increased when it is combined with Tolterodine.Approved, Investigational
TopiramateHydroflumethiazide may increase the hypokalemic activities of Topiramate.Approved
TorasemideTorasemide may increase the hypotensive activities of Hydroflumethiazide.Approved
ToremifeneHydroflumethiazide may increase the hypercalcemic activities of Toremifene.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Hydroflumethiazide.Approved, Investigational
TrandolaprilTrandolapril may increase the hypotensive activities of Hydroflumethiazide.Approved
TranilastThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Hydroflumethiazide.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Hydroflumethiazide.Approved
TravoprostTravoprost may increase the hypotensive activities of Hydroflumethiazide.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Hydroflumethiazide.Approved, Vet Approved
TriamtereneThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Triamterene.Approved
TribenosideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Tribenoside.Experimental
TrichlormethiazideHydroflumethiazide may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrihexyphenidylThe serum concentration of Hydroflumethiazide can be increased when it is combined with Trihexyphenidyl.Approved
TrimazosinTrimazosin may increase the hypotensive activities of Hydroflumethiazide.Experimental
TrimethaphanThe serum concentration of Hydroflumethiazide can be increased when it is combined with Trimethaphan.Approved
TriptolideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Triptolide.Investigational
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Hydroflumethiazide.Withdrawn
TropatepineThe serum concentration of Hydroflumethiazide can be increased when it is combined with Tropatepine.Experimental
TropicamideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Tropicamide.Approved
TrospiumThe serum concentration of Hydroflumethiazide can be increased when it is combined with Trospium.Approved
TubocurarineThe serum concentration of Hydroflumethiazide can be increased when it is combined with Tubocurarine.Approved
UdenafilUdenafil may increase the antihypertensive activities of Hydroflumethiazide.Approved, Investigational
UnoprostoneHydroflumethiazide may increase the hypotensive activities of Unoprostone.Approved
UrapidilUrapidil may increase the hypotensive activities of Hydroflumethiazide.Investigational
ValdecoxibThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Valdecoxib.Investigational, Withdrawn
ValsartanValsartan may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Hydroflumethiazide.Approved
VecuroniumThe serum concentration of Hydroflumethiazide can be increased when it is combined with Vecuronium.Approved
VenlafaxineVenlafaxine may increase the hyponatremic activities of Hydroflumethiazide.Approved
VerapamilThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Verapamil.Approved
VilanterolVilanterol may increase the hypokalemic activities of Hydroflumethiazide.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Hydroflumethiazide.Approved, Investigational
VincamineHydroflumethiazide may increase the hypotensive activities of Vincamine.Experimental
VinpocetineHydroflumethiazide may increase the hypotensive activities of Vinpocetine.Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Hydroflumethiazide.Approved, Investigational
XipamideHydroflumethiazide may increase the hypotensive activities of Xipamide.Experimental
XylometazolineHydroflumethiazide may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Hydroflumethiazide.Approved, Vet Approved
ZaltoprofenThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Zaltoprofen.Approved
ZileutonThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Zileuton.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the hyponatremic activities of Hydroflumethiazide.Withdrawn
ZofenoprilHydroflumethiazide may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Zomepirac.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference

U.S. Patent 3,254,076.

General References
  1. Moser M, Feig PU: Fifty years of thiazide diuretic therapy for hypertension. Arch Intern Med. 2009 Nov 9;169(20):1851-6. doi: 10.1001/archinternmed.2009.342. [PubMed:19901136]
External Links
Human Metabolome Database
HMDB14912
KEGG Drug
D00654
KEGG Compound
C07763
PubChem Compound
3647
PubChem Substance
46505220
ChemSpider
3521
BindingDB
25897
ChEBI
5784
ChEMBL
CHEMBL1763
Therapeutic Targets Database
DAP000747
PharmGKB
PA164752557
HET
HFZ
RxList
RxList Drug Page
ATC Codes
C03AB02 — Hydroflumethiazide and potassiumC03AA02 — HydroflumethiazideC03AH02 — Hydroflumethiazide, combinationsG01AE10 — Combinations of sulfonamides
AHFS Codes
Not Available
PDB Entries
Not Available
FDA label
Not Available
MSDS
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4WithdrawnNot AvailableHypertensive1

Pharmacoeconomics

Manufacturers
  • Wyeth ayerst laboratories
  • Par pharmaceutical inc
  • Watson laboratories inc
  • Shire development inc
Packagers
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)272-273U.S. Patent 3,254,076.
water solubility300 mg/L (at 25 °C)MERCK INDEX (1996)
logP0.36HANSCH,C ET AL. (1995)
pKa8.9BUDAVARI,S ET AL. (1996)
Predicted Properties
PropertyValueSource
Water Solubility0.858 mg/mLALOGPS
logP0.44ALOGPS
logP-0.3ChemAxon
logS-2.6ALOGPS
pKa (Strongest Acidic)9.07ChemAxon
pKa (Strongest Basic)-2.7ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area118.36 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity64.28 m3·mol-1ChemAxon
Polarizability25.68 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9636
Blood Brain Barrier-0.902
Caco-2 permeable-0.8221
P-glycoprotein substrateNon-substrate0.6668
P-glycoprotein inhibitor INon-inhibitor0.8016
P-glycoprotein inhibitor IINon-inhibitor0.787
Renal organic cation transporterNon-inhibitor0.8592
CYP450 2C9 substrateNon-substrate0.7732
CYP450 2D6 substrateNon-substrate0.8302
CYP450 3A4 substrateNon-substrate0.6442
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9232
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9544
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9324
Ames testNon AMES toxic0.8463
CarcinogenicityNon-carcinogens0.8011
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.1299 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9868
hERG inhibition (predictor II)Non-inhibitor0.8734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03dr-0759000000-a0627a1596dc3c763f34

Taxonomy

Description
This compound belongs to the class of organic compounds known as 1,2,4-benzothiadiazine-1,1-dioxides. These are aromatic heterocyclic compounds containing a 1,2,4-benzothiadiazine ring system with two S=O bonds at the 1-position.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Thiadiazines
Sub Class
Benzothiadiazines
Direct Parent
1,2,4-benzothiadiazine-1,1-dioxides
Alternative Parents
Secondary alkylarylamines / Organosulfonamides / Benzenoids / Aminosulfonyl compounds / Azacyclic compounds / Organopnictogen compounds / Organofluorides / Organic oxides / Hydrocarbon derivatives / Alkyl fluorides
Substituents
1,2,4-benzothiadiazine-1,1-dioxide / Secondary aliphatic/aromatic amine / Organosulfonic acid amide / Benzenoid / Organic sulfonic acid or derivatives / Organosulfonic acid or derivatives / Sulfonyl / Aminosulfonyl compound / Secondary amine / Azacycle
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
benzothiadiazine (CHEBI:5784)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Sodium:potassium:chloride symporter activity
Specific Function
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name
SLC12A1
Uniprot ID
Q13621
Uniprot Name
Solute carrier family 12 member 1
Molecular Weight
121449.13 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Details
2. Carbonic anhydrase 1
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide. Can hydrates cyanamide to urea.
Gene Name
CA1
Uniprot ID
P00915
Uniprot Name
Carbonic anhydrase 1
Molecular Weight
28870.0 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. doi: 10.1016/j.bmc.2008.12.023. Epub 2008 Dec 24. [PubMed:19119014]
Details
3. Carbonic anhydrase 2
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion in...
Gene Name
CA2
Uniprot ID
P00918
Uniprot Name
Carbonic anhydrase 2
Molecular Weight
29245.895 Da
References
  1. Schaeffer P, Vigne P, Frelin C, Lazdunski M: Identification and pharmacological properties of binding sites for the atypical thiazide diuretic, indapamide. Eur J Pharmacol. 1990 Jul 17;182(3):503-8. [PubMed:2226620]
  2. Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. doi: 10.1016/j.bmc.2008.12.023. Epub 2008 Dec 24. [PubMed:19119014]
Details
4. Carbonic anhydrase 4
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide. May stimulate the sodium/bicarbonate transporter activity of SLC4A4 that acts in pH homeostasis. It is essential for acid overload removal from the retina an...
Gene Name
CA4
Uniprot ID
P22748
Uniprot Name
Carbonic anhydrase 4
Molecular Weight
35032.075 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. doi: 10.1016/j.bmc.2008.12.023. Epub 2008 Dec 24. [PubMed:19119014]
Details
5. Carbonic anhydrase 9
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide. Participates in pH regulation. May be involved in the control of cell proliferation and transformation. Appears to be a novel specific biomarker for a cervic...
Gene Name
CA9
Uniprot ID
Q16790
Uniprot Name
Carbonic anhydrase 9
Molecular Weight
49697.36 Da
References
  1. Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. doi: 10.1016/j.bmc.2008.12.023. Epub 2008 Dec 24. [PubMed:19119014]
Details
6. Carbonic anhydrase 12
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide.
Gene Name
CA12
Uniprot ID
O43570
Uniprot Name
Carbonic anhydrase 12
Molecular Weight
39450.615 Da
References
  1. Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. doi: 10.1016/j.bmc.2008.12.023. Epub 2008 Dec 24. [PubMed:19119014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Steroid hormone binding
Specific Function
This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates th...
Gene Name
ATP1A1
Uniprot ID
P05023
Uniprot Name
Sodium/potassium-transporting ATPase subunit alpha-1
Molecular Weight
112895.01 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Voltage-gated potassium channel activity
Specific Function
Potassium channel activated by both membrane depolarization or increase in cytosolic Ca(2+) that mediates export of K(+). It is also activated by the concentration of cytosolic Mg(2+). Its activati...
Gene Name
KCNMA1
Uniprot ID
Q12791
Uniprot Name
Calcium-activated potassium channel subunit alpha-1
Molecular Weight
137558.115 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]

Drug created on June 13, 2005 07:24 / Updated on October 02, 2017 04:45